263 related articles for article (PubMed ID: 34052583)
1. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox.
Adel RM; Lotfy RA; Darwish AS; Amer AS
J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583
[TBL] [Abstract][Full Text] [Related]
2. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC
Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880
[TBL] [Abstract][Full Text] [Related]
3. Biochemical effects of deferasirox and deferasirox-loaded nanomicellesin iron-intoxicated rats.
Rahdar A; Hajinezhad MR; Sargazi S; Bilal M; Barani M; Karimi P; Kyzas GZ
Life Sci; 2021 Apr; 270():119146. PubMed ID: 33545199
[TBL] [Abstract][Full Text] [Related]
4. Deferasirox and vitamin D
Ghaith MM; El-Boshy M; Almasmoum H; Abdelghany AH; Azzeh FS; Almaimani RA; Idris S; Ahmad J; Mahbub AA; BaSalamah MA; Elzubeir ME; Refaat B
J Trace Elem Med Biol; 2022 Dec; 74():127085. PubMed ID: 36179462
[TBL] [Abstract][Full Text] [Related]
5. Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity.
Jiménez-Solas T; López-Cadenas F; Aires-Mejía I; Caballero-Berrocal JC; Ortega R; Redondo AM; Sánchez-Guijo F; Muntión S; García-Martín L; Albarrán B; Alonso JM; Del Cañizo C; Hernández-Hernández Á; Díez-Campelo M
Br J Haematol; 2019 Oct; 187(1):93-104. PubMed ID: 31172513
[TBL] [Abstract][Full Text] [Related]
6. An ellagic acid isolated from Clerodendrum viscosum leaves ameliorates iron-overload induced hepatotoxicity in Swiss albino mice through inhibition of oxidative stress and the apoptotic pathway.
Shendge AK; Basu T; Panja S; Chaudhuri D; Mandal N
Biomed Pharmacother; 2018 Oct; 106():454-465. PubMed ID: 29990833
[TBL] [Abstract][Full Text] [Related]
7. Potential anticancer effect of free and nanoformulated Deferasirox for breast cancer treatment:
Abdel-Wahab ND; Kabil MF; El-Sherbiny IM; Salama MF; El-Sayed G; El-Sherbini ES
Drug Dev Ind Pharm; 2024 Mar; 50(3):223-235. PubMed ID: 38305197
[TBL] [Abstract][Full Text] [Related]
8. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.
Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N
Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and Safety of Deferasirox in Thalassemia with Iron Overload: A Meta-Analysis.
Dou H; Qin Y; Chen G; Zhao Y
Acta Haematol; 2019; 141(1):32-42. PubMed ID: 30504715
[TBL] [Abstract][Full Text] [Related]
10. Deferasirox for managing iron overload in people with thalassaemia.
Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
[TBL] [Abstract][Full Text] [Related]
11. Biogenic Silver and Zero-Valent Iron Nanoparticles by Feijoa: Biosynthesis, Characterization, Cytotoxic, Antibacterial and Antioxidant Activities.
Hashemi Z; Ebrahimzadeh MA; Biparva P; Mortazavi-Derazkola S; Goli HR; Sadeghian F; Kardan M; Rafiei A
Anticancer Agents Med Chem; 2020; 20(14):1673-1687. PubMed ID: 32560617
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
Merchant R; Ahmed J; Krishnan P; Jankharia B
Indian Pediatr; 2012 Apr; 49(4):281-5. PubMed ID: 21992861
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of an oral iron chelator, deferasirox, in hemodialysis patients with iron overload.
Chen CH; Shu KH; Yang Y
Hematology; 2015 Jun; 20(5):304-10. PubMed ID: 25200910
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
Shen JC; Zhang YC; Zhao MF
Braz J Med Biol Res; 2017 Oct; 50(12):e6087. PubMed ID: 29069221
[TBL] [Abstract][Full Text] [Related]
15. Elevated total iron-binding capacity as a predictor of response to deferasirox therapy in the setting of chronic iron overload.
Watanabe J; Sato K; Horiuchi T; Kato S; Hikota R; Maekawa T; Yamamura T; Kobayashi A; Osawa Y; Kobayashi S; Kimura F
Int J Hematol; 2014 Sep; 100(3):254-9. PubMed ID: 24986748
[TBL] [Abstract][Full Text] [Related]
16. Kinetic aspects of iron(III)-chelation therapy with deferasirox (DFX) revealed by the solvolytic dissociation rate of the Fe(III)-DFX complex estimated with capillary electrophoretic reactor.
Suzuki R; Iki N
J Inorg Biochem; 2023 Apr; 241():112131. PubMed ID: 36706491
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and in vitro anticancer evaluations of two novel derivatives of deferasirox iron chelator.
Salehi S; Saljooghi ASh; Shiri A
Eur J Pharmacol; 2016 Jun; 781():209-17. PubMed ID: 27090924
[TBL] [Abstract][Full Text] [Related]
18. Deferasirox-TAT(47-57) peptide conjugate as a water soluble, bifunctional iron chelator with potential use in neuromedicine.
Goswami D; Vitorino HA; Alta RY; Silvestre DM; Nomura CS; Machini MT; Espósito BP
Biometals; 2015 Oct; 28(5):869-77. PubMed ID: 26164834
[TBL] [Abstract][Full Text] [Related]
19. Iron-chelating agents attenuate NMDA-Induced neuronal injury via reduction of oxidative stress in the rat retina.
Sakamoto K; Suzuki T; Takahashi K; Koguchi T; Hirayama T; Mori A; Nakahara T; Nagasawa H; Ishii K
Exp Eye Res; 2018 Jun; 171():30-36. PubMed ID: 29530811
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models.
Imai T; Tsuji S; Matsubara H; Ohba T; Sugiyama T; Nakamura S; Hara H; Shimazawa M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Jan; 394(1):73-84. PubMed ID: 32808069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
